Clinical trials
Phase 2 Uveitis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Unknown status | 5 |
| Terminated | 4 |
| Withdrawn | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Eye Institute (NEI) | 8 |
| ACELYRIN Inc. | 2 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Novartis Pharmaceuticals | 2 |
| Oregon Health and Science University | 2 |
| Quan Dong Nguyen | 2 |
| Wenjie Zheng | 2 |
| Aldeyra Therapeutics, Inc. | 1 |
| Allergan | 1 |
| American University of Beirut Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uveitis | 43 |
| Uveitis, Posterior | 9 |
| Uveitis, Intermediate | 8 |
| Macular Edema | 6 |
| Behcet Syndrome | 5 |
| Panuveitis | 5 |
| Retinal Diseases | 3 |
| Uveitis, Anterior | 3 |
| Inflammation | 2 |
| Retinal Vasculitis | 2 |
Trials
Showing 26 to 43 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.